Lixte Biotechnology (LIXT) Competitors $4.97 -0.08 (-1.58%) Closing price 10/7/2025 04:00 PM EasternExtended Trading$5.11 +0.14 (+2.72%) As of 07:17 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LIXT vs. WHWK, IFRX, ENTX, QNCX, CNTX, EQ, MGX, ASRT, COEP, and IMUXShould you be buying Lixte Biotechnology stock or one of its competitors? The main competitors of Lixte Biotechnology include Whitehawk Therapeutics (WHWK), InflaRx (IFRX), Entera Bio (ENTX), Quince Therapeutics (QNCX), Context Therapeutics (CNTX), Equillium (EQ), Metagenomi (MGX), Assertio (ASRT), Coeptis Therapeutics (COEP), and Immunic (IMUX). These companies are all part of the "pharmaceutical products" industry. Lixte Biotechnology vs. Its Competitors Whitehawk Therapeutics InflaRx Entera Bio Quince Therapeutics Context Therapeutics Equillium Metagenomi Assertio Coeptis Therapeutics Immunic Whitehawk Therapeutics (NASDAQ:WHWK) and Lixte Biotechnology (NASDAQ:LIXT) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment. Do analysts rate WHWK or LIXT? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Whitehawk Therapeutics 2 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Lixte Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Which has better earnings and valuation, WHWK or LIXT? Lixte Biotechnology has lower revenue, but higher earnings than Whitehawk Therapeutics. Whitehawk Therapeutics is trading at a lower price-to-earnings ratio than Lixte Biotechnology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioWhitehawk Therapeutics$25.98M4.03-$63.69M-$0.06-37.00Lixte BiotechnologyN/AN/A-$3.59M-$1.29-3.85 Do insiders & institutionals believe in WHWK or LIXT? 52.1% of Whitehawk Therapeutics shares are owned by institutional investors. Comparatively, 5.1% of Lixte Biotechnology shares are owned by institutional investors. 49.9% of Whitehawk Therapeutics shares are owned by company insiders. Comparatively, 14.8% of Lixte Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is WHWK or LIXT more profitable? Whitehawk Therapeutics has a net margin of 99.42% compared to Lixte Biotechnology's net margin of 0.00%. Lixte Biotechnology's return on equity of 0.00% beat Whitehawk Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Whitehawk Therapeutics99.42% -75.99% -68.57% Lixte Biotechnology N/A N/A -222.90% Does the media refer more to WHWK or LIXT? In the previous week, Whitehawk Therapeutics' average media sentiment score of 0.00 beat Lixte Biotechnology's score of -1.00 indicating that Whitehawk Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Whitehawk Therapeutics Neutral Lixte Biotechnology Negative Which has more volatility & risk, WHWK or LIXT? Whitehawk Therapeutics has a beta of 0.58, suggesting that its stock price is 42% less volatile than the S&P 500. Comparatively, Lixte Biotechnology has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500. SummaryWhitehawk Therapeutics beats Lixte Biotechnology on 8 of the 11 factors compared between the two stocks. Get Lixte Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for LIXT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LIXT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LIXT vs. The Competition Export to ExcelMetricLixte BiotechnologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$23.03M$3.35B$6.11B$10.65BDividend YieldN/A2.29%5.70%4.74%P/E Ratio-3.8521.4185.5426.85Price / SalesN/A466.25623.74135.13Price / CashN/A47.6737.7861.77Price / Book-4.1810.0613.116.70Net Income-$3.59M-$52.22M$3.30B$276.44M7 Day Performance3.33%4.25%3.93%2.48%1 Month Performance15.05%12.50%8.39%8.79%1 Year Performance179.21%26.68%87.02%34.41% Lixte Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LIXTLixte Biotechnology0.2977 of 5 stars$4.97-1.6%N/A+173.1%$23.03MN/A-3.854Negative NewsWHWKWhitehawk TherapeuticsN/A$1.87-2.9%N/AN/A$87.89M$21.60M-31.0821Positive NewsIFRXInflaRx2.6379 of 5 stars$1.31-4.7%$6.20+375.1%-9.8%$87.61M$180K-1.6360Positive NewsShort Interest ↑ENTXEntera Bio1.4859 of 5 stars$1.91-2.1%$10.00+423.6%+5.6%$87.21M$180K-7.3520Positive NewsQNCXQuince Therapeutics3.2227 of 5 stars$1.62+0.6%$8.14+402.6%+132.1%$86.75MN/A-1.4860CNTXContext Therapeutics3.5243 of 5 stars$0.96-0.7%$5.20+440.5%-38.3%$86.30MN/A-2.677Gap UpEQEquillium0.9919 of 5 stars$1.43-2.1%$1.00-30.1%+59.5%$85.09M$41.10M-2.5540News CoverageGap DownMGXMetagenomi3.4768 of 5 stars$2.25-2.2%$10.00+344.4%+47.5%$84.44M$52.29M-0.95236ASRTAssertio2.1186 of 5 stars$0.87-1.7%$2.38+171.7%-21.6%$84.11M$124.96M-1.9420COEPCoeptis Therapeutics1.342 of 5 stars$17.42+5.5%N/A+392.3%$84.01M$263.56K-3.012Short Interest ↓IMUXImmunic2.485 of 5 stars$0.86-8.5%$9.50+1,011.1%-42.9%$83.95MN/A-0.9170Gap Up Related Companies and Tools Related Companies WHWK Alternatives IFRX Alternatives ENTX Alternatives QNCX Alternatives CNTX Alternatives EQ Alternatives MGX Alternatives ASRT Alternatives COEP Alternatives IMUX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LIXT) was last updated on 10/8/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredU.S. Government Blocked NVIDIA’s Buyout… Here’s WhyThe U.S. government doesn't normally block billion-dollar tech deals. But when NVIDIA tried to acquire this...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredU.S. Government Sparking Crypto RallySecond Chances Don't Come Often in Crypto My "Crypto Bull Run Millionaire Blueprint" reveals everything - w...Crypto 101 Media | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lixte Biotechnology Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lixte Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
